[Ponatinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018002968
German
Original Title:
Ponatinib
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g13-02.html
Year Published:
2013
URL for published report:
https://www.iqwig.de/download/G13-02_Ponatinib_Bewertung-35a-Abs1-Satz10-SGB-V.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
Keywords
- Ponatinib
- Leukemia - Myelogenous - Chronic - Bcr-Abl Positive
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Health Care Costs
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.